benzyl N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate | 144852-23-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: benzyl N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate
• CAS: 144852-23-3
• 化学式: C₁₄H₂₀N₂O₃
• 分子量: 264.324
• InChiKey: VVRGDSMNWMSYRX-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  72.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzyl N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate 在 decamethylrhenocene 吡啶 、 对甲苯磺酰氯 作用下， 以 甲苯 为溶剂， 110.0 ℃ 、1.42 MPa 条件下， 反应 75.0h， 生成
  参考文献：
  名称：

  Chiral Ligands Containing Heteroatoms; 9.¹General Procedures for the Synthesis of Optically Active 1-(2-Pyridyl)alkylamines from α-Amino Acids

  摘要：

  介绍了从光学活性 δ± 氨基酸合成 1-(2-吡啶基)烷基胺和 N-甲基或 N,N-二甲基-1-(2-吡啶基)烷基胺的一般方法。所介绍的程序基于合适的腈与乙炔的催化共环三聚反应，可以在不损失光学纯度的情况下进行。

  DOI：

  10.1055/s-1992-26282
• 作为产物：
  描述：

  N-苄氧羰基-N-甲基-L-缬氨酸 在 N-甲基吗啉 、 ammonium hydroxide 、 氯甲酸乙酯 作用下， 生成 benzyl N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate
  参考文献：
  名称：

  Chiral Ligands Containing Heteroatoms; 9.¹General Procedures for the Synthesis of Optically Active 1-(2-Pyridyl)alkylamines from α-Amino Acids

  摘要：

  介绍了从光学活性 δ± 氨基酸合成 1-(2-吡啶基)烷基胺和 N-甲基或 N,N-二甲基-1-(2-吡啶基)烷基胺的一般方法。所介绍的程序基于合适的腈与乙炔的催化共环三聚反应，可以在不损失光学纯度的情况下进行。

  DOI：

  10.1055/s-1992-26282

文献信息

• Antiviral protease inhibitors
  申请人：Medivir AB

  公开号：US20010044547A1

  公开（公告）日：2001-11-22

  Compounds of formula (I), wherein A and A are independently the same or different group of formula (II) wherein: R′ is H, CH 3 , C(CH 3 ) 2 ,—OR a , —N(R a ) 2 , —N(R a )OR a or -DP; R is H or CH 3 ; R a is H, C 1 -C 3 alkyl; D is a bond, alkylene, —C(═O)—, —S(O)— or S(O) 2 —; P is an optionally substituted, mono or bicyclic carbo- or hetereocycle; R″ is H, any of the sidechains found in the natural amino acids, carboxacetamide, or a group (CH 2 ) n DP; M is a bond or —C(═O)N(R′″)-; Q is absent, a bond, —CH(OH)— or CH 2 —; or R″ together with Q, M and R define an optionally substituted 5 or 6 membered carbo- or heterocyclic ring which is optionally fused with a further 5 or 6 membered carbo- or heterocyclic ring; with the proviso that R is —OR a , -, N(R a ) 2 , —N(R a )OR a or -DP, if M is a bond and Q is absent; X is H, OH, OCH 3 , Y is H, OH, OCH 3 , but X and Y are not both H; Z′ and Z″ are independently —(CH 2 ) m P where P is as defined above; n and m are independently 0, 1 or 2; and pharmaceutically acceptable salts and prodrugs thereof have utility as aspartyl protease inhibitors of HIV. They can be prepared in a facile two step synthesis from novel 2,5-di-O-benzyl-L-mannaro-1,4:6,3-dilactone intermediates.

  化合物的式子（I），其中A和A独立地是式子（II）的相同或不同的基团，其中：R'是H，CH3，C（CH3）2，—ORa，—N（Ra）2，—N（Ra）ORa或-DP; R是H或CH3; Ra是H，C1-C3烷基; D是键，烷基，—C(═O)—，—S（O）—或S（O）2—; P是一个可选的取代的，单环或双环的碳或杂环；R″是H，天然氨基酸中发现的任何侧链，羧乙酰胺或一个组（CH2）nDP; M是键或—C(═O)N（R'″）-; Q不存在，是键，—CH（OH）—或CH2—; 或R″与Q、M和R一起定义一个可选的取代的5或6元环或杂环，该环可以与另一个可选的取代的5或6元环或杂环融合；条件是，如果M是键且Q不存在，则R是—ORa，-，N（Ra）2，—N（Ra）ORa或-DP；X是H，OH，OCH3，Y是H，OH，OCH3，但X和Y不都是H；Z′和Z″独立地是—（CH2）mP，其中P如上定义；n和m独立地是0、1或2；以及其药学上可接受的盐和前药具有作为HIV天冬氨酸蛋白酶抑制剂的用途。它们可以从新的2,5-二-O-苄基-L-曼纳罗-1,4:6,3-二内酯中间体中方便地进行两步合成。
• ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF
  申请人：CytomX Therapeutics, Inc.

  公开号：US20190016814A1

  公开（公告）日：2019-01-17

  The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
• MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF
  申请人：CytomX Therapeutics, Inc.

  公开号：US20210355208A1

  公开（公告）日：2021-11-18

  The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
• [EN] ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF<br/>[FR] CONJUGUÉS DE MÉDICAMENT ANTICORPS ACTIVABLES ANTI-CD71 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ABBVIE INC

  公开号：WO2019075417A1

  公开（公告）日：2019-04-18

  The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
• Chiral Ligands Containing Heteroatoms; 9.¹General Procedures for the Synthesis of Optically Active 1-(2-Pyridyl)alkylamines from α-Amino Acids
  作者：Massimo Falorni、Giorgio Chelucci、Sandra Conti、Giampaolo Giacomelli

  DOI：10.1055/s-1992-26282

  日期：——

  General syntheses of 1-(2-pyridyl)alkylamines and N-methyl or N,N-dimethyl-1-(2-pyridyl)alkylamines from optically active α-amino acids are described. The presented procedures are based on catalyzed co-cyclotrimerization of the suitable nitriles with acetylene which can be conducted without loss of optical purity.

  介绍了从光学活性 δ± 氨基酸合成 1-(2-吡啶基)烷基胺和 N-甲基或 N,N-二甲基-1-(2-吡啶基)烷基胺的一般方法。所介绍的程序基于合适的腈与乙炔的催化共环三聚反应，可以在不损失光学纯度的情况下进行。